Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$1.23M+2332.63%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lisa A. Conte
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 47
- Beta
- -0.05
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -20.02
Financials
Revenue
$1.23M+2332.6%Net Income
$-12.68MEBITDA
$-12.21MFree Cash Flow
$-5.34MEPS (diluted)
$-235.50Shares Outstanding (diluted)
53.9K+179703.3%Operating Expenses
$7.79MCash & Debt
$6.59MReturn of Capital
$0.00Revenue by Segment (annual)
$11.21MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.51M | $-53.43M | $-12059.25 |
| 2024 | $11.69M | $-38.49M | $-68611.05 |
| 2023 | $9.76M | $-41.30M | $-1409880.00 |
| 2022 | $11.96M | $-47.45M | $-28492920.00 |
| 2021 | $4.33M | $-52.59M | $-69476385.00 |
| 2020 | $9.38M | $-33.81M | $-177212295.00 |
| 2019 | $5.78M | $-38.54M | $-1596051840.00 |
| 2018 | $4.42M | $-32.15M | $-27158254770.00 |
| 2017 | $4.36M | $-21.97M | $-94883906280.00 |
| 2016 | $141.5K | $-14.73M | $-251163281340.00 |
| 2015 | $258.4K | $-16.29M | $-502326562680.00 |
| 2014 | $0.00 | $-8.61M | $-375814687635.00 |
Valuation
JAGXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (12)
- Newsaccessnewswire.com·3d ago·Negative
… to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend will consist of the Company's Series R Convertible Preferre…
View source ↗ - News247wallst.com·10d ago·Neutral
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float A rare-disease pipeline update and a thin post-split float are combining to send Jaguar Health (NASDAQ:JAGX) sharply higher. Jaguar Health stock is up 32% to $9.32 in morning trading, a surge rooted in company-specific forces.
View source ↗ - Newsbenzinga.com·11d ago·Neutral
Jaguar Health Stock Slides Thursday: What's Happening? Jaguar Health Inc. (NASDAQ:JAGX) shares are sliding Thursday afternoon as equity dilution concerns weigh on the micro-cap biopharmaceutical company following a debt-for-equity exchange.
View source ↗ - News247wallst.com·12d ago·Positive
Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4% Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn't selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.
View source ↗ - Newsaccessnewswire.com·14d ago·Negative
…crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the U.S. Food and Drug Administration (FDA) has granted Napo's request for a waiver of the fee associated with the Prescription Drug User Fee Act (PDUFA) for Mytesi ® (crofelemer delayed-release tablets) for the 2027 fiscal year. Mytesi is an FDA-approved…
View source ↗ - Newsaccessnewswire.com·21d ago·Neutral
…h common stock to begin trading on split-adjusted basis on September 17, 2026 SAN FRANCISCO, CA / ACCESS Newswire / September 15, 2026 / Jaguar Health, Inc. ( Nasdaq:JAGX ) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-15, on Thursday, September 17, 2026 (the "Effective Date") in order to support the Company's compliance with Nasdaq's listing standard…
View source ↗ - Newsbenzinga.com·25d ago·Neutral
Jaguar Health Stock Slides Thursday: What's Happening? Shares of Jaguar Health Inc. (NASDAQ:JAGX) are trading lower Thursday morning as investors evaluate the clinical development timeline for the company's rare pediatric disease pipeline following an operational update.
View source ↗ - Newsaccessnewswire.com·32d ago·Negative
…ny plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval SAN FRANCISCO, CA / ACCESS Newswire / September 4, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for treatment of intestinal failure (IF) in an infant patient due to congenital sodium diarrhea (CSD), which is caused by a mutation in the GUCY2C gene. Napo remains sharply focus…
View source ↗ - Newsaccessnewswire.com·41d ago·Positive
…s Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon SAN FRANCISCO, CA / ACCESS Newswire / August 26, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals. Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool consistency and GI fluid ba…
View source ↗ - Newsseekingalpha.com·47d ago·Neutral
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript
View source ↗ - Newsaccessnewswire.com·47d ago·Negative
…Eastern regarding Q2 2026 financials and company updates (click here to register) SAN FRANCISCO, CA / ACCESS Newswire / August 19, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated second-quarter 2026 financial results.
View source ↗ - Newsaccessnewswire.com·49d ago·Neutral
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, August 19, 2026 at 4:30 p.m. Eastern to review second-quarter 2026 financials and provide corporate updates.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-614.25 per share
Typical surprise -23.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$-2.35 vs $-7.82beat
- Wed, May 20$-2.04 vs $-10.71beat
- Tue, Apr 7$-3.14 vs $-1.49miss
- Wed, Nov 12$-2.20 vs $-1.78miss
- Thu, Aug 14$-3.59 vs $-2.50miss
- Thu, May 15$-5.84 vs $-3.79miss
Estimates and results for JAGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JAGX officers and directors.
- Bought
- $830k
- Sold
- —
16 trades
0 trades
- Micek Johnbought
- Micek Johnbought
- King Steven R.bought
- King Steven R.bought
- Siegel Jonathan B.bought
- Siegel Jonathan B.bought
- Conte Lisa Abought
- Conte Lisa Abought
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in JAGX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.